Endocervical Adenocarcinoma as a Secondary Malignancy in a Patient Treated for Non-Hodgkin's Lymphoma: A Case Report with Review of Literature

Abstract

Secondary malignancy can arise in patients with non-Hodgkin's lymphoma (NHL) on long follow-up. The risk of developing secondary malignancies is increased in NHL survivors, as compared to normal population and varies according to age, gender, and treatment modality. The nature of solid organ malignancy in order of frequency includes lung cancer followed by prostate, bladder, colon, breast, etc. Gynecological malignancy occurring in an NHL survivor is an extremely rare phenomenon with a low observed/expected ratio (0.89–0.93) as compared to other solid tumors. We hereby report a case of endocervical adenocarcinoma arising in a 51-year-old female patient who was a known treated case of NHL. This case highlights the fact that chemotherapy-induced atypia may mimic malignancy as well as the rare occurrence of gynecological cancers as a secondary malignancy in patients with NHL.

Keywords

secondary malignancy - NHL - endocervical adenocarcinoma - gynecological malignancy - case report

Patients' Consent

The authors confirm that all necessary patient consent forms have been obtained. The patient has provided written permission for their medical images and clinical details to be included in this publication. They have been informed that their identity will be protected by withholding their name and initials.

Publication History

Article published online:
10 July 2025

• References

• 1 Parsons MW, Rock C, Chipman JJ. et al. Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med 2023; 12 (03) 2624-2636
• 2 Moser O, Zimmermann M, Meyer U. et al. Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group. Haematologica 2021; 106 (05) 1390-1400
• 3 Fleury I, Chevret S, Pfreundschuh M. et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol 2016; 27 (03) 390-397
• 4 Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107 (01) 108-115
• 5 Joelsson J, Wästerlid T, Rosenquist R. et al. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Adv 2022; 6 (08) 2657-2666
• 6 Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol 2011; 22 (08) 1845-1858
• 7 Sacchi S, Marcheselli L, Bari A. et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93 (03) 398-404